Abstract. MHC molecules, also known in the human as human leukocyte antigens (HLA), display peptides on antigen presenting cell surfaces for subsequent T cell recognition. Identification of these antigenic peptides is especially important for developing peptide-based vaccines.
Introduction
T cell immune responses are responsible for fighting viruses, pathogenic bacteria and the elimination of cancer cells, and are triggered by the recognition of foreign peptide antigens bound to cell membrane expressed MHC molecules via their T cell receptors (TCR)(reviewed in [1] [2] [3] . In the human, MHC molecules are also termed human leukocyte antigens or HLA. Traditionally, identification of T cell epitopes required the synthesis of overlapping peptides (15-20 mers overlapping 10 amino acids) spanning the entire length of a protein, followed by experimental assays on each peptide such as in vitro intracellular cytokine staining [4] . This method is economically viable only for single proteins or pathogens consisting of a few proteins. As a result, computational approaches are used for the anticipation of antigenic peptides. Since T cells recognize antigenic peptides only in the context of MHC molecules [5] , methods for the anticipation of antigenic peptides rely on the prediction of peptide-MHC binding. Peptides bound to the same MHC are related by sequence similarity [6, 7] , and thus we have recently developed a method for the prediction of peptide-MHC binding based on the the use of position specific scoring matrix (PSSMs) or profiles derived from aligned peptides known to bind to MHC [8] [9, 10] A major complication to the development of T cell based immunotherapies (vaccines) using peptide antigens lies in the polymorphism of HLA molecules, which is the basis for their differential peptide binding specificity [10] . Because of the required HLA restriction and ethnic variation in HLA distribution [11] , such epitope vaccines might not be effective across populations. Conversely, developing a broadly protective multi-epitope vaccine will require the targeting of a large number of HLA molecules for peptide-binding predictions, yielding an impractical large number of peptides to work with. Interestingly, groups of several HLA molecules (supertypes) can bind largely overlapping sets of peptides [12, 13] . A systematic selection of HLA supertypic peptide binders would allow the immune response to be stimulated in individual of different genetic backgrounds. Thus, identification of HLA supertypes would facilitate the practical development of epitope-based vaccines. Here we describe a method to define HLA supertypes based on the clustering of the predicted peptide binding repertoire of HLA molecules.
In this paper, we have applied the method to class I HLA molecules (HLA I), unraveling new peptide binding relationships, and defining new supertypes. Furthermore, using the HLA I allele and haplotype gene frequencies for five major American ethnicities (Black, Caucasian, Hispanic, Native American, and Asian), we have identified combinations of supertypes that when targeted for peptide predictions are able to give a population coverage ≥ 95%, regardless of ethnicity. One of these combinations comprises 5 supertypes and is available online at our PEPVAC web server (http://immunax.dfci.harvard.edu/PEPVAC/). The selected supertypes with the included alleles (in parenthesis) are the following: A2 (A*0201-07, A*0209, A*6802), A3 (A*0301, A*1101, A*3101, A*3301, A*6801, A*6601), A24 (A*2402, B*3801), B7 (B*0702, B*3501, B*5101-02, B*5301, B*5401), B15 (A*0101, B*1501_B62, B1502). The PEPVAC resource also allows the prediction of proteasomal cleavage using language models [14] . Identification of promiscuous peptide binders to these supertypes using PEPVAC reduces the total number of predicted epitopes without compromising population coverage, thus being useful for the design of multi-epitope vaccines.
Matherial and Methods

MHCI-peptide binding repertoire
Peptide-binding repertoires of the 55 HLA I molecules considered in this study consisted of sets of peptides that were predicted to bind to the relevant HLA I molecules. Peptide binding predictions were obtained from a random protein of 1000 amino acids in length (swiss-prot amino acid distribution), using position specific scoring matrices (PSSMs) obtained from aligned peptides known to bind to that HLA I molecule [9, 10] . The peptide binding repertoire for each HLA I molecule consisted of the 2% top scoring peptides, and thus was composed of 20 peptides. PSSMs used in this study were all obtained from peptides of 9 residues in length (9mers), and thereby predicted peptide binders were all 9mers.
Supertype construction.
HLA I supertypes were derived by clustering the peptide-binding repertoire overlap of HLA I as it is illustrated in Fig. 1 . First, the overlap between the peptidebinding repertoire of any two pairs of HLA I molecules was computed as the number of peptides binders shared by the two HLA I molecules. Let that number be n ij , where i and j, represent the peptide binding repertoire of the HLA I molecules i and j, respectively. Subsequently, a distance coefficient (d ij ) was obtained as follows:
Where N is the total number of peptides considered in the predicted peptide binding repertoire of any HLA I molecule, and is equal to 20 (peptide binding repertoire consisted 2% of top scoring peptides from a random protein of 1000 amino acids; see above). Thus, if the peptide binding repertoire between two HLA I molecules is identical, then d ij = 0. Alternatively, if they share no peptides in common, then d ij = 20. Consequently, a quadratic distance matrix was derived containing the d ij coefficient for all distinct pair of HLA I molecules. Finally, clustering of the peptide-binding overlap was carried from this distance matrix using the clustering algorithms in the Phylogeny Inference Package (PHYLIP) [15] , and the relationship were visualized in the form of a phylogenic tree. 
Results and Discussion
Identification of HLA I supertypes.
Sidney, Sette and co-workers [12, 13] (hereafter Sidney-Sette et al) described the first HLA I supertypes by carefully inspection of the reported peptide binding motifs of individual HLA alleles. While we acknowledge the pioneering work of these authors, the relationships between peptide binding specificities of HLA molecules may be too subtle to be defined by visual inspection of these peptide binding motifs. Furthermore, such sequence patterns have proven to be too simple to describe the binding ability of a peptide to a given MHC molecule [16, 17] . In view of these limitations, we have developed an alternative method to define HLA supertypes (outlined in Fig. 1 and described in Material and Methods). The core of the method consists of the generation of a distance matrix whose coefficients are inversely proportional to the peptide binders shared by any two HLA molecules (Fig. 1) . Subsequently, this distance matrix is fed to a phylogenic clustering algorithm to establish the kinship among the distinct HLA peptide binding repertoires. Fig. 2 shows a phylogenic tree built upon the peptide binding repertoire of 55 HLA I molecules using a Fitch and Margoliash clustering algorithm [18] . In this representation, HLA I alleles with overlapping peptide binding repertoires (similar peptide binding specificities) branch together in groups or clusters, and we have identified as supertypes those clusters including alleles with at least a 20% overlap in their peptide-binding repertoire (pairwise)(highlighted in Fig. 2) . It is important to indicate, that relationships between the HLA I peptide binding specificities noted in this study are restricted by the available HLA I binding repertoires obtained using our profiles, and relationships might shift in the future as the result of increasing the number of HLA I binding repertoires considered. As expected, our analysis indicates that the overlap between the peptide binding specificities of HLA I molecules is mostly confined to alleles belonging to the same gene. Nevertheless, it has also become apparent that peptidebinding overlap exists between alleles belonging to the HLA-A and HLA-B genes (Fig. 2, B15 cluster; B*4402 and A*2902; and A*2402 and B*3801). Relationships between the peptide binding specificities of HLA-A and HLA-B alleles (as well as new defined supertypes) would need experimental confirmation, but nevertheless it suggest that peptide-vaccine development would benefit from this inter gene cross-presentation. Cross-presentation of peptide in the context of two different HLA I genes might increase the frequency at which a peptide is recognized, thereby increasing its potential immunogenicity. 
Supertypes and population coverage studies.
Supertypes defined in this study include the A2, A3, B7, B27 and B44 supertypes previously identified by Sidney-Sette et al. In our analysis, the alleles included in these supertypes match very well to those described earlier. However, there are discrepancies that extent beyond the limits imposed by the availability of profiles to obtain the peptide binding repertoire to specific HLA I alleles. The B27 supertype we defined here is more restricted than that proposed by Sidney-Sette et al, that also included the B*1509, B*1510, and B*3801 alleles, among others. The B7 supertype defined by Sidney-Sette et al. included the B*1508 allele, whereas in our analysis, B*1508 cluster with the A*0101, and B*1501-02 alleles (Fig. 1, B15 supertype) . Sidney-Sette et al also described a potential A24 supertype including the alleles A*2301, A*2402 and A*3001. We do not have profiles for the prediction of peptide binding to A*2301 or A*3001, but nevertheless with the available profiles the A*2402 binding specificity seems to be closer to that of B*3801. In addition, a new interesting peptide binding relationship includes that between the A*2902 and B*4002 alleles. Also, following our study we have defined two new supertypes, BX and B57. The BX supertype would include the alleles B*1509, B*1510 and B*39011, and B57 includes the alleles B*5801, B*5701-02, and B*1513.
The cumulative phenotypic frequency (CPF) of the supertypes defined in this study is shown in Table I . CPF was calculated by 5 distinct American ethic groups (Black, Caucasian, Hispanic, North America Natives and Asian), and it represents the population coverage that would be provided by a vaccine consisting of epitopes restricted by the alleles included in the supertype. The A2, A3 and B7 supertypes have the largest CPF in the 5 studied ethnic groups, and in fact, taken together, they provide a CPF close to 90%, irrespective of ethnicity. To increase the population coverage to ≥ 95% regardless of ethnicity it is necessary to include at least two more supertypes. Specifically, the supertypes A2, A3, B7, B15 and A24 or B44 represent the minimal supertypic combination with the largest population coverage. Note that the supertype B57, despite its quite large CPF, is not included in this minimal supertypic combination since alleles in the B57 supertype are in linkage disequilibrium with other alleles included in more prevalent supertypes. Cumulative phenotype frequency was obtained using the HLA I gene and haplotype frequencies published by published by Cao et al [19] corresponding to the indicated 5 American ethnic groups. Method for computing the cumulative phenotype frequency considered the disequilibrium linkage between the HLA-A and -B gene and was based on that reported by Dawson et al [20] *North American Natives.
Tool for the design of epitope-based vaccines.
Prediction of promiscuous peptide-binders of supertypes that include highly prevalent alleles in the human population provides a head start to the development of broadly covering epitope-based vaccines. With that objective, we have implemented a tool that allow the prediction of promiscuous peptide binders to the supertypes A2, A3, B7, B15 and A24 ( Fig. 1 and Table I ), which have a CPF greater than 95%, irrespective of ethnicity. We named this tool PEPVAC (Promiscous Epitopes based VACcines), and it is online at the site http://immunax.dfci.harvard.edu/PEPVAC/ hosted by the Molecular Immunology Foundation/Dana-Farber Cancer Institute. The web interface to PEPVAC (shown in Fig. 3A) allows targetting of any combination of the mentioned selected supertypes, displaying CPF of the selected supertypes. Fig. 3 . The PEPVAC web server. A) PEPVAC input page. The page is divided into the following sections: E-MAIL, GENOMES, SUPERTYPES, AND PROTEASOMAL CLEAVAGE. Basically, the server allows the targetting of pathogenic organisms (GENOMES section) for the prediction of promiscous peptide binders to any combination of the supertypes A2, A3, B7, A24, and B15. The CPF of the selected supertypes is calculated on-the-fly and shown on the relevant window. Prediction of proteasomal cleavage using three optimal language models are carried out in parallel to the peptide binding predictions (PROTEASOMAL CLEAVAGE section). B) PEPVAC result page. In the example shown, the A3 supertype was selected for peptide binding predictions from the genome of Influenza A virus. The result page first displays a summary of the predictions which reports the chosen selections, the number of predicted peptides and the minimum population coverage provided by the supertypic selection, followed by the predicted peptide binders to each of the selected supertypes. Peptides are ranked by score, and are predicted to bind to all alleles included in the supertype. Relevant information about each sorted peptide includes its protein source as well as its molecular weight. Peptides shown in violet contain a C-terminal residue that is predicted to be the result of proteasomal cleavage. If the proteasomal cleavage filter is checked ON in the input page, only violet peptides will be shown.
MHCI-restricted epitopes derive from protein fragments generated by the protease activity of the proteasome, and it is thought that the C-terminus of any MHCIrestricted epitope is the result of the original proteasomal cleavage [21] . Consequently, in PEPVAC we have combined the predictions of promiscuous supertypic peptide binders using profiles, with probabilistic models that indicate whether a C-terminus of a given peptide is likely be the result of proteosomal cleavage. Probabilistic models for proteasomal cleavage were generated from a set of known epitopes restricted by human HLA I molecules, as indicated elsewhere [14] . Promiscuous peptide binders containing a C-terminal end predicted to be the result of proteasomal cleavage are shown in violet in the result page (Fig. 3. B) . Threshold for the prediction of promiscuous peptide binders in PEPVAC have been fixed to provide a reduced and manageable set of promiscuous peptide-binders to each supertype. As an example, predicted promiscuous peptides to the above 5 supertypes from a genome such as that of Influenza virus A (4160 amino acids distributed in 10 distinct open reading frames (ORF)), represents only 5.51% (254 9mer peptides) of all possible peptides (4617 9mer peptides). Furthermore, this figure further contracts to 170 peptides (3.7% of all 9mer peptides from Influenza virus A genome) if only those peptides that are predicted to be cleaved by the proteasome are considered. Thus, PEPVAC is well fit to provide genome-wide predictions of promiscuous HLA I restricted epitopes at a practical scale for the development multi-epitope vaccines against pathogenic organisms and offering a broad population coverage.
